By Kamal Choudhury (Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

The US drug regulator has missed a deadline for granting full approval to Novavax's COVID-19 vaccine, the company said ...

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal approval ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. HealthDay News — The US Food and Drug Administration (FDA) has delayed the full ...